Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali
Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali
复制标题
DOI：
10.1016/j.vaccine.2004.01.054
复制
发表时间：
2004-08-13
期刊：
影响因子：
5.5
通讯作者：
Doumbo, OK
中科院分区：
文献类型：
--
作者：
Lyke, KE;Dicko, A;Doumbo, OK
血期疟疾疫苗功效试验的潜在终点包括无并发症的疟疾疾病（很难与其他发热性疾病区分开来）和死亡率（需要过大的样本量）。在病死率已知的情况下，严格定义的严重疟疾可预测与疟疾相关的死亡率。为了评估严重疟疾作为试验终点的适宜性，我们于 1999 年进行了一次人口普查，并测量了马里班迪亚加拉 1999 年至 2001 年严重疟疾的发病率。儿童严重疟疾的年发病率
Potential endpoints for blood stage malaria vaccine efficacy trials include uncomplicated malaria disease, which is hard to differentiate from other febrile illnesses, and mortality, which requires prohibitively large sample sizes. Strictly defined severe malaria predicts malaria-associated mortality where case fatality rates are known. To assess the suitability of severe malaria as a trial endpoint, we conducted a census in 1999 and measured the incidence of severe malaria from 1999 to 2001 in Bandiagara, Mali. The annual incidence of severe malaria in children